Related Experiment Video
Updated: Jun 22, 2026
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
A multicenter, randomized, placebo-controlled trial of prophylactic recombinant granulocyte-colony stimulating factor
Pierre Kuhn1, Jean Messer, Alain Paupe
1Réanimation néonatale, Service de Pédiatrie 2, Hôpital de Hautepierre, CHRU Strasbourg, France. pierre.kuhn@chru-strasbourg.fr
Objective:
To test the hypothesis that prophylactic treatment of neutropenic premature neonates with recombinant granulocyte-colony stimulating factor (rG-CSF) would reduce the incidence of nosocomial infections (NIs).
Study Design:
A total of 25 neonatal intensive care units participated in this multicenter, randomized, double-blind, placebo-controlled trial. Premature infants of gestational age (GA)
Results:
A total of 102 infants received rG-CSF (mean GA, 29.2 weeks), and 98 received placebo (mean GA, 29.1 weeks). Survival free of confirmed infection for 4 weeks after treatment was 74/102 in the rG-CSF group and 66/98 in the placebo group (P = .42). However, during 2 weeks, there was a significant difference between groups (86/102 vs 70/98; P = .028).
Conclusions:
In this population, prophylactic rG-CSF did not significantly increase survival free of infection at 4 weeks after treatment. The transient effect observed at 2 weeks in the most immature infants should be evaluated further.
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
01:01Regulation of Hematopoietic Stem Cells